Back to results
US 2008/0167312 A1Published application
Preparation and utility of substituted allylamines
AssigneeAuspex Pharmaceuticals, Inc.
InventorsThomas G. Gant, Sepehr Sarshar
Life of this patent
Estimating the term…
Abstract
Disclosed herein are substituted allylamines having structural Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and the methods of their use thereof.
Claims109
A compound having structural Formula I
- or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein:
- R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24 and R25 are independently selected from the group consisting of hydrogen and deuterium;
- at least one of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24 and R25 is deuterium;
- and
- with the proviso that a compound having structural Formula I cannot be
2 more elements
A compound selected from the group consisting of:
- or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
A compound selected from the group consisting of:
- or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
The compound:
- or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
A method of treating a mammal suffering from an infectious disorder, comprising administering to said subject a therapeutically effective amount of a compound of Formula I;
- wherein said compound of Formula I has the structure:
- or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein:
- R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24 and R25 are independently selected from the group consisting of hydrogen and deuterium;
- and
- at least one of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24 and R25 is deuterium.
2 more elements
Dependencies are inferred from the claim text.